SUMMARY Prostaglandin E2 was given orally to 59 infants with ductus dependent congenital heart disease, and intravenous infusions were substituted for varying periods in 27 of them. The E type prostaglandins are widely used to maintain the patency of the ductus arteriosusl-3 and thus improve the metabolic condition of neonates with reduced pulmonary blood flow or the coarctation syndrome. The use of prostaglandin E1 (PGE1) has been particularly well documented, and as a result of a multicentre study in the United States, comprehensive reports of its effectiveness2 and side effects4 have been produced. Previous reports from this hospital described our earlier experience using prostaglandin E2 (PGE2) and highlighted the advantages of the oral preparation for both emergency and long term use.3 5 6 We showed that oral PGE2 was easily administered and was rapidly and consistently effective. Its side effects seemed to have been less severe than those of intravenous PGE1 or PGE2
The E type prostaglandins are widely used to maintain the patency of the ductus arteriosusl-3 and thus improve the metabolic condition of neonates with reduced pulmonary blood flow or the coarctation syndrome. The use of prostaglandin E1 (PGE1) has been particularly well documented, and as a result of a multicentre study in the United States, comprehensive reports of its effectiveness2 and side effects4 have been produced. Previous reports from this hospital described our earlier experience using prostaglandin E2 (PGE2) and highlighted the advantages of the oral preparation for both emergency and long term use.3 5 6 We showed that oral PGE2 was easily administered and was rapidly and consistently effective. Its side effects seemed to have been less severe than those of intravenous PGE1 or PGE2 treatment. We showed that when it was necessary to give PGE2 intravenously, a dose one tenth of that usually suggested would suffice. 6 Recently, the effectiveness of intravenous PGE1 in a similar dosage has been confirmed. 7 We have established a policy of beginning treatment with the oral preparation of PGE2 and of using low dose intravenous treatment only when vomiting, diarrhoea, or severe acidosis lessen the likelihood of reliable gastrointestinal absorption. In most cases treatment continues for several weeks to try to reduce the risks of palliative or corrective surgery and to encourage growth of the infants. Although the oral preparation of PGE2 is not available in many countries, it has been used by centres besides our own in the United Kingdom.8 9 There has not previously been a comprehensive report of the use of oral and low dose intravenous PGE2 in a large series of patients, and it is our purpose to offer a critical evaluation of the advantages and side effects.
Patients and methods
The study began in 1979, having been approved by the research ethical committees of the hospital and the district health authority. Some of the data on the first 12 patients have been reported previously6 and are included in the present report in order to present our overall experience. We first week of life in 53 infants (85%) and on the first day in 28 (45%).
Treatment was usually begun using the oral preparation of PGE2 but in 10 infants there was reason to believe that gastrointestinal absorption would be poor, and a low dosage, intravenous infusion was used instead. Intravenous treatment was also substituted when oral treatment was ineffective, or if the infant developed gastrointestinal complications. Oral treatment was then reintroduced at the earliest opportunity. Prostaglandin E2 was given orally to 59 infants, of whom 27 also received intravenous treatment, for periods ranging from a few hours to 38 days. Three patients were given intravenous treatment only. The duration of treatment was determined both by the response to treatment and by the clinical assessment of the optimal time for surgery. The response was assessed by the clinical condition of the infant, and, where indicated, by arterial blood gas analysis. The initial oral dose ranged from 15 to 60 sg/kg per hour, and the dosage interval was gradually increased after the first week while carefully monitoring the response.
The initial intravenous dose was 0*003 to 0*006 [tg/kg per minute, and was increased if necessary to a maximum of 0-02 ug/kg per minute.
In the longer term, growth of the infant was monitored and in those in whom more than one cardiac catheterisation was performed, the diameter of the right pulmonary artery was measured.6 Eight patients had skeletal surveys, and plasma alkaline phosphatase activity was measured in 18.
Results
In 60 infants there was initial clinical and biochemical improvement during PGE2 treatment. Two infants did not improve: in one there was an anatomical explanation-at necropsy the ductus arteriosus, main pulmonary artery, and left branch were absent, the right pulmonary artery arising from the ascending aorta. Eight infants had an unsatisfactory overall response to orally administered PGE2; five were successfully treated instead with intravenous PGE2 and three had operations. In one other infant who had been treated for 46 days, an operation was not considered to be possible and treatment was stopped.
Duration and method of treatment. The mean duration of treatment was 49 days, the range being 6 hours to 272 days. Sixteen infants were treated for less than 1 week, 19 for 1 to 4 weeks, 15 for 4 to 12 weeks, and 12 for more than 12 weeks. Ten patients who had vomiting or diarrhoea or severe acidosis at presentation were treated initially with intravenous prostaglandins because it was considered that absorption of the oral preparation would be unreliable. Seven of them subsequently received oral treatment.
Another five received intravenous treatment after they had responded poorly to oral treatment; two of these responded again to oral treatment later. Fourteen patients, after an initial period of oral treatment, were treated intravenously because of diarrhoea (10 patients), necrotising enterocolitis (three patients), or pneumonia (one patient).
Dosage. The oral starting dose was mean (SD) 28 (14) ,ug/kg per hour, the maximum dose was mean (SD) 45 
Discussion
The efficacy of intravenous and oral PGE2 treatment in maintaining ductus arteriosus patency has been well documented.1 6 8 9 Whenever possible, we have used the oral preparation in preference to the intravenous because it is easier to administer and its absorption and beneficial effects are rapid. It is particularly suitable for long term use, and has enabled most infants so treated to grow satisfactorily.8 9 As a result of having been able to increase the interval between doses, a few infants were discharged from hospital and were given oral PGE2 at home. We have also confirmed our earlier observation that intravenous doses as low as 0-003 jg/kg per minute are effective for both initial and long term use.
Several infants considered to be inoperable at presentation because of small pulmonary arteries subsequently had successful shunt operations. McMahon et a18 found that the pulmonary artery size increased in only four of 11 patients treated for two to eight months with oral PGE2. They compared pulmonary artery diameter at initial angiogram with that measured at operation. In our study, the pulmonary artery diameter increased in nine of the 10 patients who had angiography before and after treatment with PGE2. Our results do not enable us to show whether the long term outlook of the group as a whole has been improved by delaying surgery, but our surgical colleagues prefer to operate on infants weighing 3-5 kg or more. The small group of patients with interrupted aortic arch, however, showed no long term benefit; although their acid base balance improved they remained in congestive cardiac failure and did not thrive.
The short term use of prostaglandins is well established and we suggest that in selected patients a longer period of treatment will allow growth. Long term treatment may be undertaken safely, effectively, and simply by using the oral route. We recommend the oral administration of PGE2 in an initial dose of 20 to 25 Rg/kg hourly, decreasing the frequency of doses after the first week. When gastrointestinal absorption is expected to be poor or when oral treatment is ineffective we begin an intravenous infusion at a dose of 0-003 rg/kg per minute, rarely needing to increase the dose for more than a few hours, and exceptionally using a dose as high as 0*01 to 0*02 rig/kg per minute. Our current practice is to treat this group of patients with oral PGE2 for between one and four weeks initially, and then to decide, on an individual basis, whether to proceed with surgery or to plan a longer course of treatment to encourage further growth. 
